Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: A 5-year review

Vox Sanguinis

Volumn 104, Issue 2, 2013, Pages 93-99

  Cable, R ^a   Lelie, N ^b   Bird, A ^a  

^a Western Province Blood Transfusion Service   (South Africa)

^b Lelie Research   (France)

Author keywords

Blood donation testing; High throughput testing; NAT testing

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ACUTE DISEASE; ARTICLE; BLOOD DONOR; BLOOD SAFETY; CHRONIC DISEASE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SOUTH AFRICA; TRANSFUSION TRANSMITTED VIRAL INFECTION; VIRUS INFECTION;

ALGORITHMS; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RISK FACTORS; RNA, VIRAL; SEROLOGIC TESTS; SOUTH AFRICA;

EID: 84872617491     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01640.x     Document Type: Article

References (21)

1. Shisana O, Rehle T, Simbayi LC et al. and the SABSSM III Implementation Team: South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning Tide Among Teenagers? Cape Town, HSRC Press, 2009.
2. Heyns Adu P, Benjamin RJ, Swanevelder JPR, et al. : Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA 2006; 295:519-526
3. Bekker L-G, Wood R: Blood safety - at what cost? JAMA 2006; 295:557-558
4. Allain JP, Belkhiri D, Vermeulen M, et al. : Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009; 49:1868-1876
5. Weusten J, Vermeulen M, Van Drimmelen H, et al. : Refinement of a viral transmission risk model for blood donations screened by NAT in different pool sizes and repeat test algorithms. Transfusion 2011; 51:203-215
6. Busch MP, Glynn SA, Stramer SL, et al. : A new strategy for estimating the risks of transfusion - transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254-264
7. Kleinman SH, Lelie PN, Busch MP: Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49:2454-2489
8. Ma ZM, Stone M, Piatak M Jr, et al. : High specific infectivity of plasma virus from the pre-ramp up and ramp up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288-3297
9. Komiya Y, Katayama K, Yugi H, et al. : Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48:286-294
10. Tabuchi A, Tanaka J, Katayama K, et al. : Titration of hepatitis B virus activity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008; 80:2064-2068
11. Stolz M, Lelie N, Tinguely C, et al. : Efficacy of individual nucleic acid testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low endemic region. Transfusion 2010; 50:2695-2706
12. Vermeulen M, Dickens C, Lelie N, et al. : Hepatitis B virus transmission by blood transfusion during 4years of individual donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012; 52:880-892
13. Vermeulen M, Lelie PN, Sykes W, et al. : Impact of individual donation nucleic acid testing on the risk of human immunodeficiency virus, hepatitis B virus and hepatitis C virus transmission in South African donors. Transfusion 2009; 49:1115-1125
14. Vermeulen M, Coleman C, Gaggia L, et al. : The effect of change in testing strategy and increasing the black donor base on the HIV window period transmission risk in South Africa: a 5year analysis. Vox Sang 2011; 101(Suppl 1):41-3D (Abstract)
15. Vermeulen M, Lelie N, Reddy R: Recent insights in testing for transfusion transmissible viral infections. ISBT Science Series 2011; 6:29-233
16. Busch MP, Operskalski EA, Mosley JW, et al. : Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis 1996; 174:26
17. Kleinman SH, Van Drimmelen H, Lelie N, et al. : Minipool NAT HIV-breakthrough transmission case and probability of interdiction by current small pool or individual NAT screening systems. Vox Sang 2009; 96(Suppl 1):3D-S23 p53 (Abstract)
18. Deeks SG, Walker BD: Human immunodeficiency virus controllers: mechanisms of durable viral control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416
19. Gerlich WH, Wagner FF, Chudy M, et al. : HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007; 79:S32-S36
20. Abdool Karim SS, Coovadia HM, Windsor IM, et al. : The prevalence and transmission of hepatitis B infection in urban, rural, and insitutionalised black children in Natal/Kwazulu, South Africa. Int J Epidemiol 1986; 17:168-173
21. Phikulsod S, Oota S, Tirawatnapong T, et al. : One-year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 2009; 49:1126-1135